June 8, 2021: Dr. Diana Zuckerman, president of NCHR, speaks out against FDA’s approval of the ineffective Alzheimer’s drug aduhelm.
Read More »We’re In The News
As a respected nonprofit health research center, our views are often quoted in the media, including newspapers, magazines, TV, radio, and websites. We also write articles and blogs for a number of different and highly respected newspapers, magazines, and popular websites, and we are published in prestigious medical journals and health policy publications. We frequently express our policy views in letters to government officials and public comments to federal agencies and we sometimes release statements or press releases on newsworthy issues.
Please e-mail info@center4research.org or call 202-223-4000 with your inquiries. We can assist you with scheduling interviews with the NCHR President, Dr. Diana Zuckerman, and other experts on our staff.
The Role of Environmental Regulations in the Fight Against Cancer
NYC NPR, May 10, 2021: President Biden wants a new agency within NIH to “end cancer as we know it.” Dr. Diana Zuckerman explains to NPR that EPA needs to do more to help prevent cancer.
Read More »Teens are worried about wrinkles. Here’s how Gen Z is helping to fuel a beauty boom
CNN, May 6, 2021: While teens are increasingly spending time and money to prevent wrinkles, experts are concerned about the premature demand for more invasive treatments.
Read More »Biden’s ‘end cancer’ pledge begs for environmental oversight
E&E News, May 4, 2021: President Biden pledged last week to “end cancer as we know it,” a bold promise focused on boosting funding to the National Institutes of Health for a special Advanced Research Projects Agency-Health. But public health experts who have spent their careers examining environmental causes of cancer say it may not be possible to truly stop cancer without EPA stepping in.
Read More »To Stay: Two More Cancer Indications With ‘Dangling Approvals’
Medscape News, April 29, 2021: Two more cancer indications that had been granted accelerated approval by the US Food and Drug Administration (FDA) are going to stay in place, at least for now. This was the verdict after the second day of a historic 3-day meeting (April 27–29) and follows a similar verdict from day one.
Read More »